Subtitle
Risk of temporal lobe necrosis between proton beam and volumetric modulated arc therapies in patients with different head and neck cancers.
Subtitle
Risk of temporal lobe necrosis between proton beam and volumetric modulated arc therapies in patients with different head and neck cancers.
Proto therapy Time
September and October 2023
Executive summary
This study reviewed 483 patients with various types of head and neck cancer (HNC), and reported that the nasopharyngeal carcinoma (NPC) patients had a higher frequency of temporal lobe necrosis (TLN) compared to non PNC patients (5.6% vs. 0.4%, p < 0.01). The frequency of TLN was similar between patients receiving PBT and those receiving VMAT (PBT vs. VMAT: 4.7% vs. 6.3%, p = 0.76). The authors concluded that their study demonstrated that patients with NPC were susceptible to TLN during the early period after RT. In addition, PBT may be associated with an equivalent risk of TLN when compared with VMAT in patients with NPC or other HNCs.
Top cancer treatments
Related contents
Proton Therapy Publication
September 2024
The Potential and Challenges of Proton FLASH in Head and Neck Cancer Reirradiation.
Proton Therapy Publication
May 2024
Long-Term Outcomes Following Definitive or Adjuvant Proton Radiotherapy for Adenoid Cystic Carcinoma.
Proton Therapy Publication
June 2024
Long-term outcomes after particle radiation therapy in patients with nasopharyngeal adenoid cystic carcinoma.
Proton Therapy Publication
May 2024
Current Status and Future Directions of Proton Therapy for Head and Neck Carcinoma.
Proton Therapy Publication
August 2024
Proton Therapy in The Treatment of Head And Neck Cancers- Review.
Webinar
Phase III randomized trial of IMPT versus IMRT for the treatment of head and neck oropharyngeal carcinoma (OPC)
An Interview with Dr. Steven Frank
Steven
Frank
Proton Therapy Publication
June 2024
Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT)
Proton Therapy Publication
April 2024
Proton FLASH radiotherapy ameliorates radiation-induced salivary gland dysfunction and oral mucositis and increases survival in a mouse model of head and neck cancer.